3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Endometrial Neoplasms
7
Uterine Cervical Neoplasms
5
Leiomyoma
4
Ovarian Neoplasms
3
Myofibroma
3
Uterine Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Dysplasia
1
Sarcoma
1
Metrorrhagia
1
Menorrhagia
1
Hysterectomy
1
Hereditary Breast and Ovarian Cancer Syndrome
1
Fallopian Tube Neoplasms
1
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
1
Endometrial Hyperplasia
1
Disease
1
Carcinoma, Squamous Cell
1
Carcinoma, Endometrioid
1
Carcinoma, Adenosquamous
1
Adenocarcinoma
1
Interventions
temsirolimus
1
sintilimab
1
pembrolizumab
1
palbociclib
1
olaparib
1
durvalumab
1
defactinib
1
copanlisib
1
ceralasertib
1
Therapeutics
1
Restraint, Physical
1
Radiation, Ionizing
1
RO5126766
1
Megestrol Acetate
1
Medroxyprogesterone Acetate
1
Hysterectomy
1
Fulvestrant
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Carcinoma, Endometrioid
×
Hysterectomy
×
Clear all
NCT02598219
2026-03-18
SENTIRAD
Centre Oscar Lambret
Phase 3
Active not recruiting
262 enrolled